NO328767B1 - Acylerte 6,7,8,9-tetrehydro-5H-benzocykloheptenyl-aminer, anvendelse derav, farmasoytisk preparat inneholdende minst en slik forbindelse samt fremgangsmate for fremstilling av forbindelsene - Google Patents

Info

Publication number

NO328767B1

NO328767B1 NO20033566A NO20033566A NO328767B1 NO 328767 B1 NO328767 B1 NO 328767B1 NO 20033566 A NO20033566 A NO 20033566A NO 20033566 A NO20033566 A NO 20033566A NO 328767 B1 NO328767 B1 NO 328767B1

Authority

NO

Norway

Prior art keywords

tetrahydro

benzocyclohepten

group

alkyl

phenyl

Prior art date

2001-02-13

Links

• Espacenet
• Global Dossier
• Discuss

• 150000001875 compounds Chemical class 0.000 title claims description 110
• 238000000034 method Methods 0.000 title claims description 21
• RTSRUUJKIOUOCT-UHFFFAOYSA-N 6,7,8,9-tetrahydro-5h-benzo[7]annulen-4-amine Chemical class C1CCCCC2=C1C=CC=C2N RTSRUUJKIOUOCT-UHFFFAOYSA-N 0.000 title claims description 19
• 239000000825 pharmaceutical preparation Substances 0.000 title claims description 12
• -1 C1-C8- alkoxy Chemical group 0.000 claims description 213
• 150000003839 salts Chemical class 0.000 claims description 73
• 125000001424 substituent group Chemical group 0.000 claims description 46
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 42
• 239000000203 mixture Substances 0.000 claims description 39
• 229910052736 halogen Inorganic materials 0.000 claims description 29
• 150000002367 halogens Chemical class 0.000 claims description 25
• 125000001072 heteroaryl group Chemical group 0.000 claims description 23
• 125000000217 alkyl group Chemical group 0.000 claims description 22
• 125000003118 aryl group Chemical group 0.000 claims description 16
• 125000000623 heterocyclic group Chemical group 0.000 claims description 16
• 239000000243 solution Substances 0.000 claims description 14
• 238000011282 treatment Methods 0.000 claims description 13
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 12
• 125000002577 pseudohalo group Chemical group 0.000 claims description 12
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
• 230000003511 endothelial effect Effects 0.000 claims description 11
• 230000014509 gene expression Effects 0.000 claims description 10
• 125000005842 heteroatom Chemical group 0.000 claims description 9
• 229910052760 oxygen Inorganic materials 0.000 claims description 9
• 229910052757 nitrogen Inorganic materials 0.000 claims description 8
• 125000004076 pyridyl group Chemical group 0.000 claims description 8
• 229910052717 sulfur Inorganic materials 0.000 claims description 8
• 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 7
• 239000008177 pharmaceutical agent Substances 0.000 claims description 7
• AVYNORNFILBJTK-UHFFFAOYSA-N 2-methyl-n-(6,7,8,9-tetrahydro-5h-benzo[7]annulen-6-yl)-3h-benzimidazole-5-carboxamide Chemical compound C1CCC2=CC=CC=C2CC1NC(=O)C1=CC=C(NC(C)=N2)C2=C1 AVYNORNFILBJTK-UHFFFAOYSA-N 0.000 claims description 6
• 201000001320 Atherosclerosis Diseases 0.000 claims description 6
• 102000008299 Nitric Oxide Synthase Human genes 0.000 claims description 6
• 108010021487 Nitric Oxide Synthase Proteins 0.000 claims description 6
• 125000001931 aliphatic group Chemical group 0.000 claims description 6
• MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 claims description 6
• 201000010099 disease Diseases 0.000 claims description 6
• 229910052731 fluorine Inorganic materials 0.000 claims description 6
• 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 6
• 125000004178 (C1-C4) alkyl group Chemical class 0.000 claims description 5
• 239000003814 drug Substances 0.000 claims description 5
• 238000004519 manufacturing process Methods 0.000 claims description 5
• 239000003826 tablet Substances 0.000 claims description 5
• 125000000027 (C1-C10) alkoxy group Chemical group 0.000 claims description 4
• 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 4
• QQNCYZSKHBXQMP-UHFFFAOYSA-N 2,4-dimethyl-n-(6,7,8,9-tetrahydro-5h-benzo[7]annulen-6-yl)-1,3-thiazole-5-carboxamide Chemical compound S1C(C)=NC(C)=C1C(=O)NC1CC2=CC=CC=C2CCC1 QQNCYZSKHBXQMP-UHFFFAOYSA-N 0.000 claims description 4
• SGMNKIYUPGAEHW-UHFFFAOYSA-N 2,6-dimethyl-n-(6,7,8,9-tetrahydro-5h-benzo[7]annulen-6-yl)pyridine-3-carboxamide Chemical compound CC1=NC(C)=CC=C1C(=O)NC1CC2=CC=CC=C2CCC1 SGMNKIYUPGAEHW-UHFFFAOYSA-N 0.000 claims description 4
• CNPROWSZFLRYJA-UHFFFAOYSA-N 2-amino-n-(6,7,8,9-tetrahydro-5h-benzo[7]annulen-6-yl)pyridine-3-carboxamide Chemical compound NC1=NC=CC=C1C(=O)NC1CC2=CC=CC=C2CCC1 CNPROWSZFLRYJA-UHFFFAOYSA-N 0.000 claims description 4
• MRGLZNLNWSFZRY-UHFFFAOYSA-N 3-pyrrolidin-1-yl-n-(6,7,8,9-tetrahydro-5h-benzo[7]annulen-6-yl)benzamide Chemical compound C1CCC2=CC=CC=C2CC1NC(=O)C(C=1)=CC=CC=1N1CCCC1 MRGLZNLNWSFZRY-UHFFFAOYSA-N 0.000 claims description 4
• QCNJNGNTRWMPNN-UHFFFAOYSA-N 4-fluoro-n-(6,7,8,9-tetrahydro-5h-benzo[7]annulen-6-yl)benzamide Chemical compound C1=CC(F)=CC=C1C(=O)NC1CC2=CC=CC=C2CCC1 QCNJNGNTRWMPNN-UHFFFAOYSA-N 0.000 claims description 4
• DKVHOEYPLXMCKN-UHFFFAOYSA-N 5-methyl-n-(6,7,8,9-tetrahydro-5h-benzo[7]annulen-6-yl)pyrazine-2-carboxamide Chemical compound C1=NC(C)=CN=C1C(=O)NC1CC2=CC=CC=C2CCC1 DKVHOEYPLXMCKN-UHFFFAOYSA-N 0.000 claims description 4
• 206010002383 Angina Pectoris Diseases 0.000 claims description 4
• 208000024172 Cardiovascular disease Diseases 0.000 claims description 4
• 208000002249 Diabetes Complications Diseases 0.000 claims description 4
• 206010020772 Hypertension Diseases 0.000 claims description 4
• 239000002253 acid Substances 0.000 claims description 4
• 229910052799 carbon Inorganic materials 0.000 claims description 4
• 208000029078 coronary artery disease Diseases 0.000 claims description 4
• 239000003937 drug carrier Substances 0.000 claims description 4
• 239000007903 gelatin capsule Substances 0.000 claims description 4
• 238000002347 injection Methods 0.000 claims description 4
• 239000007924 injection Substances 0.000 claims description 4
• 229920006395 saturated elastomer Polymers 0.000 claims description 4
• 230000001225 therapeutic effect Effects 0.000 claims description 4
• 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims description 3
• 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 3
• 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 3
• IHQUENCAKSKBOG-UHFFFAOYSA-N 2,5-dimethyl-1-(pyridin-4-ylmethyl)pyrrole-3-carboxylic acid Chemical compound CC1=CC(C(O)=O)=C(C)N1CC1=CC=NC=C1 IHQUENCAKSKBOG-UHFFFAOYSA-N 0.000 claims description 3
• CFXZFMJPGVBGQZ-UHFFFAOYSA-N 3-amino-n-(6,7,8,9-tetrahydro-5h-benzo[7]annulen-6-yl)pyrazine-2-carboxamide Chemical compound NC1=NC=CN=C1C(=O)NC1CC2=CC=CC=C2CCC1 CFXZFMJPGVBGQZ-UHFFFAOYSA-N 0.000 claims description 3
• 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 3
• LGDKWLPTGZRTAA-UHFFFAOYSA-N 6-methyl-2-(methylamino)-n-(6,7,8,9-tetrahydro-5h-benzo[7]annulen-6-yl)pyridine-3-carboxamide Chemical compound CNC1=NC(C)=CC=C1C(=O)NC1CC2=CC=CC=C2CCC1 LGDKWLPTGZRTAA-UHFFFAOYSA-N 0.000 claims description 3
• 206010012655 Diabetic complications Diseases 0.000 claims description 3
• 206010048554 Endothelial dysfunction Diseases 0.000 claims description 3
• 229910006074 SO2NH2 Inorganic materials 0.000 claims description 3
• 208000007718 Stable Angina Diseases 0.000 claims description 3
• 208000006011 Stroke Diseases 0.000 claims description 3
• 229910052794 bromium Inorganic materials 0.000 claims description 3
• 229910052801 chlorine Inorganic materials 0.000 claims description 3
• 239000008298 dragée Substances 0.000 claims description 3
• 230000002526 effect on cardiovascular system Effects 0.000 claims description 3
• 239000000839 emulsion Substances 0.000 claims description 3
• 230000008694 endothelial dysfunction Effects 0.000 claims description 3
• 239000007943 implant Substances 0.000 claims description 3
• 238000001802 infusion Methods 0.000 claims description 3
• 239000003094 microcapsule Substances 0.000 claims description 3
• JTEUAQLTMFIFGG-UHFFFAOYSA-N n-(6,7,8,9-tetrahydro-5h-benzo[7]annulen-6-yl)-1h-indole-6-carboxamide Chemical compound C1CCC2=CC=CC=C2CC1NC(=O)C1=CC=C(C=CN2)C2=C1 JTEUAQLTMFIFGG-UHFFFAOYSA-N 0.000 claims description 3
• 239000007922 nasal spray Substances 0.000 claims description 3
• 239000006187 pill Substances 0.000 claims description 3
• 230000008569 process Effects 0.000 claims description 3
• 208000002815 pulmonary hypertension Diseases 0.000 claims description 3
• 239000007940 sugar coated tablet Substances 0.000 claims description 3
• 239000000829 suppository Substances 0.000 claims description 3
• 239000006188 syrup Substances 0.000 claims description 3
• 235000020357 syrup Nutrition 0.000 claims description 3
• 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims description 2
• 125000004463 2,4-dimethyl-thiazol-5-yl group Chemical group CC=1SC(=C(N1)C)* 0.000 claims description 2
• 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 2
• MITXLYNRFCATDU-UHFFFAOYSA-N 3-amino-5,6-dimethyl-n-(6,7,8,9-tetrahydro-5h-benzo[7]annulen-6-yl)pyrazine-2-carboxamide Chemical compound N1=C(C)C(C)=NC(N)=C1C(=O)NC1CC2=CC=CC=C2CCC1 MITXLYNRFCATDU-UHFFFAOYSA-N 0.000 claims description 2
• 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 claims description 2
• 125000004863 4-trifluoromethoxyphenyl group Chemical group [H]C1=C([H])C(OC(F)(F)F)=C([H])C([H])=C1* 0.000 claims description 2
• USSMIQWDLWJQDQ-UHFFFAOYSA-N 5-methyl-1-phenylpyrazole-4-carboxylic acid Chemical compound CC1=C(C(O)=O)C=NN1C1=CC=CC=C1 USSMIQWDLWJQDQ-UHFFFAOYSA-N 0.000 claims description 2
• VNONBOMIMRWFCW-KRWDZBQOSA-N 6-(methoxymethyl)-n-[(6s)-6,7,8,9-tetrahydro-5h-benzo[7]annulen-6-yl]pyridine-3-carboxamide Chemical compound C1=NC(COC)=CC=C1C(=O)N[C@@H]1CC2=CC=CC=C2CCC1 VNONBOMIMRWFCW-KRWDZBQOSA-N 0.000 claims description 2
• KKJUPNGICOCCDW-UHFFFAOYSA-N 7-N,N-Dimethylamino-1,2,3,4,5-pentathiocyclooctane Chemical compound CN(C)C1CSSSSSC1 KKJUPNGICOCCDW-UHFFFAOYSA-N 0.000 claims description 2
• 208000004476 Acute Coronary Syndrome Diseases 0.000 claims description 2
• 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 2
• 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 2
• 125000004649 C2-C8 alkynyl group Chemical group 0.000 claims description 2
• 208000010228 Erectile Dysfunction Diseases 0.000 claims description 2
• 208000007530 Essential hypertension Diseases 0.000 claims description 2
• 206010016654 Fibrosis Diseases 0.000 claims description 2
• 206010018367 Glomerulonephritis chronic Diseases 0.000 claims description 2
• 206010019280 Heart failures Diseases 0.000 claims description 2
• 208000001132 Osteoporosis Diseases 0.000 claims description 2
• 201000003099 Renovascular Hypertension Diseases 0.000 claims description 2
• 208000017442 Retinal disease Diseases 0.000 claims description 2
• 206010038923 Retinopathy Diseases 0.000 claims description 2
• 201000004239 Secondary hypertension Diseases 0.000 claims description 2
• 208000007536 Thrombosis Diseases 0.000 claims description 2
• 208000007814 Unstable Angina Diseases 0.000 claims description 2
• 206010047281 Ventricular arrhythmia Diseases 0.000 claims description 2
• 230000033115 angiogenesis Effects 0.000 claims description 2
• 208000006673 asthma Diseases 0.000 claims description 2
• 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims description 2
• 125000005605 benzo group Chemical group 0.000 claims description 2
• 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims description 2
• 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims description 2
• 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
• 125000002618 bicyclic heterocycle group Chemical group 0.000 claims description 2
• 208000020832 chronic kidney disease Diseases 0.000 claims description 2
• 125000005390 cinnolyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 claims description 2
• 230000007882 cirrhosis Effects 0.000 claims description 2
• 208000019425 cirrhosis of liver Diseases 0.000 claims description 2
• 229940124558 contraceptive agent Drugs 0.000 claims description 2
• 239000003433 contraceptive agent Substances 0.000 claims description 2
• 238000005859 coupling reaction Methods 0.000 claims description 2
• 230000006378 damage Effects 0.000 claims description 2
• 239000008187 granular material Substances 0.000 claims description 2
• 125000002883 imidazolyl group Chemical group 0.000 claims description 2
• 201000001881 impotence Diseases 0.000 claims description 2
• 125000001041 indolyl group Chemical group 0.000 claims description 2
• 125000005956 isoquinolyl group Chemical group 0.000 claims description 2
• 125000000842 isoxazolyl group Chemical group 0.000 claims description 2
• 210000004185 liver Anatomy 0.000 claims description 2
• 208000010125 myocardial infarction Diseases 0.000 claims description 2
• BCDWJKJBNRSDDL-UHFFFAOYSA-N n-(6,7,8,9-tetrahydro-5h-benzo[7]annulen-6-yl)-4-(2,2,2-trifluoroethoxy)benzamide Chemical compound C1=CC(OCC(F)(F)F)=CC=C1C(=O)NC1CC2=CC=CC=C2CCC1 BCDWJKJBNRSDDL-UHFFFAOYSA-N 0.000 claims description 2
• 239000002674 ointment Substances 0.000 claims description 2
• 125000002971 oxazolyl group Chemical group 0.000 claims description 2
• 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 2
• 125000003373 pyrazinyl group Chemical group 0.000 claims description 2
• 125000003226 pyrazolyl group Chemical group 0.000 claims description 2
• 125000002098 pyridazinyl group Chemical group 0.000 claims description 2
• 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 claims description 2
• 125000000714 pyrimidinyl group Chemical group 0.000 claims description 2
• 125000000168 pyrrolyl group Chemical group 0.000 claims description 2
• 125000005493 quinolyl group Chemical group 0.000 claims description 2
• 239000007921 spray Substances 0.000 claims description 2
• 239000000725 suspension Substances 0.000 claims description 2
• 125000000335 thiazolyl group Chemical group 0.000 claims description 2
• 125000001544 thienyl group Chemical group 0.000 claims description 2
• 125000005843 halogen group Chemical group 0.000 claims 4
• NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 claims 1
• FUXGIWUFWCCHHY-UHFFFAOYSA-N 6-pyrrolidin-1-yl-n-(6,7,8,9-tetrahydro-5h-benzo[7]annulen-6-yl)pyridine-3-carboxamide Chemical compound C1CCC2=CC=CC=C2CC1NC(=O)C(C=N1)=CC=C1N1CCCC1 FUXGIWUFWCCHHY-UHFFFAOYSA-N 0.000 claims 1
• 201000001068 Prinzmetal angina Diseases 0.000 claims 1
• 208000009325 Variant Angina Pectoris Diseases 0.000 claims 1
• 239000000443 aerosol Substances 0.000 claims 1
• 230000001476 alcoholic effect Effects 0.000 claims 1
• 208000022831 chronic renal failure syndrome Diseases 0.000 claims 1
• 239000007822 coupling agent Substances 0.000 claims 1
• 206010012601 diabetes mellitus Diseases 0.000 claims 1
• 230000037406 food intake Effects 0.000 claims 1
• 229940097496 nasal spray Drugs 0.000 claims 1
• 201000001119 neuropathy Diseases 0.000 claims 1
• 230000007823 neuropathy Effects 0.000 claims 1
• 230000002093 peripheral effect Effects 0.000 claims 1
• 208000033808 peripheral neuropathy Diseases 0.000 claims 1
• 230000004936 stimulating effect Effects 0.000 claims 1
• 230000002194 synthesizing effect Effects 0.000 claims 1
• 229940098465 tincture Drugs 0.000 claims 1
• 230000014759 maintenance of location Effects 0.000 description 147
• 238000000926 separation method Methods 0.000 description 45
• 150000001412 amines Chemical class 0.000 description 40
• DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 31
• 101710090055 Nitric oxide synthase, endothelial Proteins 0.000 description 27
• MDVRGZASGHPBAG-UHFFFAOYSA-N 6,7,8,9-tetrahydro-5h-benzo[7]annulen-6-amine Chemical compound C1C(N)CCCC2=CC=CC=C21 MDVRGZASGHPBAG-UHFFFAOYSA-N 0.000 description 26
• 102100028452 Nitric oxide synthase, endothelial Human genes 0.000 description 24
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 18
• MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 18
• YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
• 230000000694 effects Effects 0.000 description 13
• 241000699670 Mus sp. Species 0.000 description 11
• 241001465754 Metazoa Species 0.000 description 10
• 238000002360 preparation method Methods 0.000 description 10
• 239000002904 solvent Substances 0.000 description 10
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 9
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
• 230000015572 biosynthetic process Effects 0.000 description 8
• 238000013518 transcription Methods 0.000 description 8
• 230000035897 transcription Effects 0.000 description 8
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 7
• 125000003342 alkenyl group Chemical group 0.000 description 7
• 125000003545 alkoxy group Chemical group 0.000 description 7
• 210000001105 femoral artery Anatomy 0.000 description 7
• 230000009467 reduction Effects 0.000 description 7
• 238000003786 synthesis reaction Methods 0.000 description 7
• UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
• ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
• ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
• 238000006243 chemical reaction Methods 0.000 description 6
• 125000000753 cycloalkyl group Chemical group 0.000 description 6
• 230000002950 deficient Effects 0.000 description 6
• IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 6
• 229910000041 hydrogen chloride Inorganic materials 0.000 description 6
• 239000007787 solid Substances 0.000 description 6
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
• 101150037123 APOE gene Proteins 0.000 description 5
• 101100216294 Danio rerio apoeb gene Proteins 0.000 description 5
• 208000034827 Neointima Diseases 0.000 description 5
• 230000004913 activation Effects 0.000 description 5
• 210000004027 cell Anatomy 0.000 description 5
• 208000035475 disorder Diseases 0.000 description 5
• 210000003038 endothelium Anatomy 0.000 description 5
• 238000002474 experimental method Methods 0.000 description 5
• 239000000543 intermediate Substances 0.000 description 5
• 239000011541 reaction mixture Substances 0.000 description 5
• 238000012360 testing method Methods 0.000 description 5
• 102000013918 Apolipoproteins E Human genes 0.000 description 4
• 108010025628 Apolipoproteins E Proteins 0.000 description 4
• 239000004475 Arginine Substances 0.000 description 4
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
• WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
• KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
• ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 4
• JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
• 241000283984 Rodentia Species 0.000 description 4
• WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
• 210000000709 aorta Anatomy 0.000 description 4
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 4
• WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 4
• 230000033228 biological regulation Effects 0.000 description 4
• 239000011575 calcium Substances 0.000 description 4
• 239000000969 carrier Substances 0.000 description 4
• 238000004296 chiral HPLC Methods 0.000 description 4
• HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
• 210000002889 endothelial cell Anatomy 0.000 description 4
• 230000006870 function Effects 0.000 description 4
• JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
• BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
• 239000000902 placebo Substances 0.000 description 4
• 229940068196 placebo Drugs 0.000 description 4
• 230000036316 preload Effects 0.000 description 4
• 239000000126 substance Substances 0.000 description 4
• 230000002103 transcriptional effect Effects 0.000 description 4
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
• OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
• JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 3
• IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 3
• MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
• KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
• PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
• QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
• YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
• 229960000583 acetic acid Drugs 0.000 description 3
• 230000002378 acidificating effect Effects 0.000 description 3
• 230000010933 acylation Effects 0.000 description 3
• 238000005917 acylation reaction Methods 0.000 description 3
• 125000002947 alkylene group Chemical group 0.000 description 3
• 238000010171 animal model Methods 0.000 description 3
• 230000036523 atherogenesis Effects 0.000 description 3
• 239000002585 base Substances 0.000 description 3
• 239000000872 buffer Substances 0.000 description 3
• 125000004432 carbon atom Chemical group C* 0.000 description 3
• 239000003795 chemical substances by application Substances 0.000 description 3
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
• 125000000392 cycloalkenyl group Chemical group 0.000 description 3
• 239000003925 fat Substances 0.000 description 3
• 238000001914 filtration Methods 0.000 description 3
• 238000004128 high performance liquid chromatography Methods 0.000 description 3
• 238000001727 in vivo Methods 0.000 description 3
• 230000006698 induction Effects 0.000 description 3
• 238000002844 melting Methods 0.000 description 3
• 230000008018 melting Effects 0.000 description 3
• 229960003966 nicotinamide Drugs 0.000 description 3
• 239000011570 nicotinamide Substances 0.000 description 3
• 230000010412 perfusion Effects 0.000 description 3
• 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 description 3
• 230000007505 plaque formation Effects 0.000 description 3
• 230000001124 posttranscriptional effect Effects 0.000 description 3
• 238000011321 prophylaxis Methods 0.000 description 3
• 229910052938 sodium sulfate Inorganic materials 0.000 description 3
• 235000011152 sodium sulphate Nutrition 0.000 description 3
• RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
• OBEBYDRMPFIEBF-UHFFFAOYSA-N 1-phenyl-n-(6,7,8,9-tetrahydro-5h-benzo[7]annulen-6-yl)-5-(trifluoromethyl)pyrazole-4-carboxamide Chemical compound FC(F)(F)C1=C(C(=O)NC2CC3=CC=CC=C3CCC2)C=NN1C1=CC=CC=C1 OBEBYDRMPFIEBF-UHFFFAOYSA-N 0.000 description 2
• SRGHTELVPDTMSI-UHFFFAOYSA-N 1h-benzo[7]annulen-1-amine Chemical class C1=CC=CC=C2C(N)C=CC=C21 SRGHTELVPDTMSI-UHFFFAOYSA-N 0.000 description 2
• HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
• QHTUFTCTWAXAER-UHFFFAOYSA-N 2-amino-4,6-dimethyl-n-(6,7,8,9-tetrahydro-5h-benzo[7]annulen-6-yl)pyridine-3-carboxamide Chemical compound NC1=NC(C)=CC(C)=C1C(=O)NC1CC2=CC=CC=C2CCC1 QHTUFTCTWAXAER-UHFFFAOYSA-N 0.000 description 2
• VEEMQOZWURTFME-UHFFFAOYSA-N 2-methyl-n-(6,7,8,9-tetrahydro-5h-benzo[7]annulen-6-yl)-6-(trifluoromethyl)pyridine-3-carboxamide Chemical compound CC1=NC(C(F)(F)F)=CC=C1C(=O)NC1CC2=CC=CC=C2CCC1 VEEMQOZWURTFME-UHFFFAOYSA-N 0.000 description 2
• QTGBFOMQKCOSEE-UHFFFAOYSA-N 2-methyl-n-(6,7,8,9-tetrahydro-5h-benzo[7]annulen-6-yl)pyridine-3-carboxamide Chemical compound CC1=NC=CC=C1C(=O)NC1CC2=CC=CC=C2CCC1 QTGBFOMQKCOSEE-UHFFFAOYSA-N 0.000 description 2
• QRRXHOTUIZVRFS-UHFFFAOYSA-N 2-morpholin-4-yl-n-(6,7,8,9-tetrahydro-5h-benzo[7]annulen-6-yl)pyridine-4-carboxamide Chemical compound C1CCC2=CC=CC=C2CC1NC(=O)C(C=1)=CC=NC=1N1CCOCC1 QRRXHOTUIZVRFS-UHFFFAOYSA-N 0.000 description 2
• 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
• KAOQNAKWZFVUTC-UHFFFAOYSA-N 2-pyrrolidin-1-yl-n-(6,7,8,9-tetrahydro-5h-benzo[7]annulen-6-yl)pyridine-4-carboxamide Chemical compound C1CCC2=CC=CC=C2CC1NC(=O)C(C=1)=CC=NC=1N1CCCC1 KAOQNAKWZFVUTC-UHFFFAOYSA-N 0.000 description 2
• NBRBENMMDFDNRP-UHFFFAOYSA-N 3-(dimethylamino)-n-(6,7,8,9-tetrahydro-5h-benzo[7]annulen-6-yl)benzamide Chemical compound CN(C)C1=CC=CC(C(=O)NC2CC3=CC=CC=C3CCC2)=C1 NBRBENMMDFDNRP-UHFFFAOYSA-N 0.000 description 2
• RFIINYICEOOZSG-UHFFFAOYSA-N 4,6-dimethyl-n-(6,7,8,9-tetrahydro-5h-benzo[7]annulen-6-yl)pyridine-3-carboxamide Chemical compound C1=NC(C)=CC(C)=C1C(=O)NC1CC2=CC=CC=C2CCC1 RFIINYICEOOZSG-UHFFFAOYSA-N 0.000 description 2
• OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
• VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
• KCBWAFJCKVKYHO-UHFFFAOYSA-N 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-[[4-[1-propan-2-yl-4-(trifluoromethyl)imidazol-2-yl]phenyl]methyl]pyrazolo[3,4-d]pyrimidine Chemical compound C1(CC1)C1=NC=NC(=C1C1=NC=C2C(=N1)N(N=C2)CC1=CC=C(C=C1)C=1N(C=C(N=1)C(F)(F)F)C(C)C)OC KCBWAFJCKVKYHO-UHFFFAOYSA-N 0.000 description 2
• QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
• RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
• QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
• PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
• VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
• YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
• AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
• 101000610640 Homo sapiens U4/U6 small nuclear ribonucleoprotein Prp3 Proteins 0.000 description 2
• CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
• AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
• 239000012359 Methanesulfonyl chloride Substances 0.000 description 2
• UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
• NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
• 239000004698 Polyethylene Substances 0.000 description 2
• 108700008625 Reporter Genes Proteins 0.000 description 2
• 101001110823 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-A Proteins 0.000 description 2
• 101000712176 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-B Proteins 0.000 description 2
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
• YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
• 102100040374 U4/U6 small nuclear ribonucleoprotein Prp3 Human genes 0.000 description 2
• XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
• FPQVGDGSRVMNMR-JCTPKUEWSA-N [[(z)-(1-cyano-2-ethoxy-2-oxoethylidene)amino]oxy-(dimethylamino)methylidene]-dimethylazanium;tetrafluoroborate Chemical compound F[B-](F)(F)F.CCOC(=O)C(\C#N)=N/OC(N(C)C)=[N+](C)C FPQVGDGSRVMNMR-JCTPKUEWSA-N 0.000 description 2
• 150000007513 acids Chemical class 0.000 description 2
• 239000000654 additive Substances 0.000 description 2
• WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
• 150000001298 alcohols Chemical class 0.000 description 2
• 125000004450 alkenylene group Chemical group 0.000 description 2
• 125000000304 alkynyl group Chemical group 0.000 description 2
• 150000001413 amino acids Chemical class 0.000 description 2
• 125000003277 amino group Chemical group 0.000 description 2
• 239000005557 antagonist Substances 0.000 description 2
• 238000013459 approach Methods 0.000 description 2
• 210000001367 artery Anatomy 0.000 description 2
• 125000001769 aryl amino group Chemical group 0.000 description 2
• 125000004104 aryloxy group Chemical group 0.000 description 2
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
• 230000036772 blood pressure Effects 0.000 description 2
• 210000004204 blood vessel Anatomy 0.000 description 2
• 229910052791 calcium Inorganic materials 0.000 description 2
• 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
• 230000003197 catalytic effect Effects 0.000 description 2
• 239000000460 chlorine Substances 0.000 description 2
• 235000012000 cholesterol Nutrition 0.000 description 2
• 238000004587 chromatography analysis Methods 0.000 description 2
• 230000001684 chronic effect Effects 0.000 description 2
• 230000001419 dependent effect Effects 0.000 description 2
• XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
• 239000002270 dispersing agent Substances 0.000 description 2
• 239000003480 eluent Substances 0.000 description 2
• 239000000796 flavoring agent Substances 0.000 description 2
• 239000011737 fluorine Substances 0.000 description 2
• 235000013355 food flavoring agent Nutrition 0.000 description 2
• 235000019253 formic acid Nutrition 0.000 description 2
• 125000000524 functional group Chemical group 0.000 description 2
• 239000012362 glacial acetic acid Substances 0.000 description 2
• 230000000004 hemodynamic effect Effects 0.000 description 2
• 230000006872 improvement Effects 0.000 description 2
• 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 2
• 239000003112 inhibitor Substances 0.000 description 2
• 230000005764 inhibitory process Effects 0.000 description 2
• TWBYWOBDOCUKOW-UHFFFAOYSA-N isonicotinic acid Chemical compound OC(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-N 0.000 description 2
• 239000004310 lactic acid Substances 0.000 description 2
• 235000014655 lactic acid Nutrition 0.000 description 2
• 150000002632 lipids Chemical class 0.000 description 2
• 239000007788 liquid Substances 0.000 description 2
• 238000011068 loading method Methods 0.000 description 2
• 230000007246 mechanism Effects 0.000 description 2
• QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 2
• 150000007522 mineralic acids Chemical class 0.000 description 2
• 125000001624 naphthyl group Chemical group 0.000 description 2
• 125000004957 naphthylene group Chemical group 0.000 description 2
• 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
• 239000003921 oil Substances 0.000 description 2
• 235000019198 oils Nutrition 0.000 description 2
• 150000007524 organic acids Chemical class 0.000 description 2
• 230000003647 oxidation Effects 0.000 description 2
• 238000007254 oxidation reaction Methods 0.000 description 2
• 239000012188 paraffin wax Substances 0.000 description 2
• WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
• 239000012071 phase Substances 0.000 description 2
• WLJVNTCWHIRURA-UHFFFAOYSA-N pimelic acid Chemical compound OC(=O)CCCCCC(O)=O WLJVNTCWHIRURA-UHFFFAOYSA-N 0.000 description 2
• 229920005862 polyol Polymers 0.000 description 2
• 150000003077 polyols Chemical class 0.000 description 2
• 239000002243 precursor Substances 0.000 description 2
• 238000002953 preparative HPLC Methods 0.000 description 2
• 239000000047 product Substances 0.000 description 2
• 230000035755 proliferation Effects 0.000 description 2
• 230000000069 prophylactic effect Effects 0.000 description 2
• 125000006239 protecting group Chemical group 0.000 description 2
• 108090000623 proteins and genes Proteins 0.000 description 2
• 210000003492 pulmonary vein Anatomy 0.000 description 2
• 238000000746 purification Methods 0.000 description 2
• UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
• LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
• 230000004044 response Effects 0.000 description 2
• YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
• 239000000741 silica gel Substances 0.000 description 2
• 229910002027 silica gel Inorganic materials 0.000 description 2
• 238000010898 silica gel chromatography Methods 0.000 description 2
• 239000007858 starting material Substances 0.000 description 2
• 238000001356 surgical procedure Methods 0.000 description 2
• JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
• 125000003944 tolyl group Chemical group 0.000 description 2
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
• 230000001052 transient effect Effects 0.000 description 2
• 230000002792 vascular Effects 0.000 description 2
• 230000002861 ventricular Effects 0.000 description 2
• 238000005303 weighing Methods 0.000 description 2
• 238000001262 western blot Methods 0.000 description 2
• MDVRGZASGHPBAG-NSHDSACASA-N (6s)-6,7,8,9-tetrahydro-5h-benzo[7]annulen-6-amine Chemical compound C1[C@@H](N)CCCC2=CC=CC=C21 MDVRGZASGHPBAG-NSHDSACASA-N 0.000 description 1
• BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
• HSZJMDBOSZVDOK-UHFFFAOYSA-N 1-(4-chlorophenyl)-5-(trifluoromethyl)pyrazole-4-carboxylic acid Chemical compound FC(F)(F)C1=C(C(=O)O)C=NN1C1=CC=C(Cl)C=C1 HSZJMDBOSZVDOK-UHFFFAOYSA-N 0.000 description 1
• USFOWWTYLXZHQP-UHFFFAOYSA-N 1-(4-fluorophenyl)-3,5-dimethyl-n-(6,7,8,9-tetrahydro-5h-benzo[7]annulen-6-yl)pyrazole-4-carboxamide Chemical compound CC1=C(C(=O)NC2CC3=CC=CC=C3CCC2)C(C)=NN1C1=CC=C(F)C=C1 USFOWWTYLXZHQP-UHFFFAOYSA-N 0.000 description 1
• PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
• FTURKFDGZGUUOJ-UHFFFAOYSA-N 1-methyl-3-oxo-n-(6,7,8,9-tetrahydro-5h-benzo[7]annulen-6-yl)-2,4-dihydroquinoxaline-6-carboxamide Chemical compound C1CCC2=CC=CC=C2CC1NC(=O)C1=CC=C2N(C)CC(=O)NC2=C1 FTURKFDGZGUUOJ-UHFFFAOYSA-N 0.000 description 1
• 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
• VWLAJXVEUUCNGS-UHFFFAOYSA-N 1-propan-2-yl-n-(6,7,8,9-tetrahydro-5h-benzo[7]annulen-6-yl)-2-(trifluoromethyl)benzimidazole-5-carboxamide Chemical compound C1CCC2=CC=CC=C2CC1NC(=O)C1=CC=C2N(C(C)C)C(C(F)(F)F)=NC2=C1 VWLAJXVEUUCNGS-UHFFFAOYSA-N 0.000 description 1
• 238000005160 1H NMR spectroscopy Methods 0.000 description 1
• DWEJGHKFUUXWEC-UHFFFAOYSA-N 2,4-difluoro-n-(6,7,8,9-tetrahydro-5h-benzo[7]annulen-6-yl)benzamide Chemical compound FC1=CC(F)=CC=C1C(=O)NC1CC2=CC=CC=C2CCC1 DWEJGHKFUUXWEC-UHFFFAOYSA-N 0.000 description 1
• SMPDWVIGIRUOGC-UHFFFAOYSA-N 2,4-dimethyl-n-(6,7,8,9-tetrahydro-5h-benzo[7]annulen-6-yl)-1,3-oxazole-5-carboxamide Chemical compound O1C(C)=NC(C)=C1C(=O)NC1CC2=CC=CC=C2CCC1 SMPDWVIGIRUOGC-UHFFFAOYSA-N 0.000 description 1
• HROMUVZPHORXKZ-UHFFFAOYSA-N 2,4-dimethyl-n-(6,7,8,9-tetrahydro-5h-benzo[7]annulen-6-yl)pyrimidine-5-carboxamide Chemical compound CC1=NC(C)=NC=C1C(=O)NC1CC2=CC=CC=C2CCC1 HROMUVZPHORXKZ-UHFFFAOYSA-N 0.000 description 1
• ONOOGYUYUYRXNQ-UHFFFAOYSA-N 2,5-dimethyl-1-(pyridin-4-ylmethyl)-n-(6,7,8,9-tetrahydro-5h-benzo[7]annulen-6-yl)pyrrole-3-carboxamide Chemical compound CC1=CC(C(=O)NC2CC3=CC=CC=C3CCC2)=C(C)N1CC1=CC=NC=C1 ONOOGYUYUYRXNQ-UHFFFAOYSA-N 0.000 description 1
• CIRVCSCFJALBOH-UHFFFAOYSA-N 2,5-dimethyl-1-phenylpyrrole-3-carboxylic acid Chemical compound CC1=CC(C(O)=O)=C(C)N1C1=CC=CC=C1 CIRVCSCFJALBOH-UHFFFAOYSA-N 0.000 description 1
• CNKOEMJMLKPJLT-UHFFFAOYSA-N 2,5-dimethyl-n-(6,7,8,9-tetrahydro-5h-benzo[7]annulen-6-yl)-1h-pyrrole-3-carboxamide Chemical compound N1C(C)=CC(C(=O)NC2CC3=CC=CC=C3CCC2)=C1C CNKOEMJMLKPJLT-UHFFFAOYSA-N 0.000 description 1
• GRWVTJVWGHKYQC-HNNXBMFYSA-N 2,5-dimethyl-n-[(6s)-6,7,8,9-tetrahydro-5h-benzo[7]annulen-6-yl]pyrazole-3-carboxamide Chemical compound CN1N=C(C)C=C1C(=O)N[C@@H]1CC2=CC=CC=C2CCC1 GRWVTJVWGHKYQC-HNNXBMFYSA-N 0.000 description 1
• DWPRJVXKQCFURP-UHFFFAOYSA-N 2,6-bis(dimethylamino)pyrimidine-4-carboxylic acid Chemical compound CN(C)C1=CC(C(O)=O)=NC(N(C)C)=N1 DWPRJVXKQCFURP-UHFFFAOYSA-N 0.000 description 1
• BZZYJGAALZBESL-UHFFFAOYSA-N 2,6-dichloro-n-(6,7,8,9-tetrahydro-5h-benzo[7]annulen-6-yl)pyridine-3-carboxamide Chemical compound ClC1=NC(Cl)=CC=C1C(=O)NC1CC2=CC=CC=C2CCC1 BZZYJGAALZBESL-UHFFFAOYSA-N 0.000 description 1
• WCZRSHFRVKZEFA-UHFFFAOYSA-N 2,6-dimethoxy-n-(6,7,8,9-tetrahydro-5h-benzo[7]annulen-6-yl)pyridine-3-carboxamide Chemical compound COC1=NC(OC)=CC=C1C(=O)NC1CC2=CC=CC=C2CCC1 WCZRSHFRVKZEFA-UHFFFAOYSA-N 0.000 description 1
• PLTAUCRWFSTPNT-UHFFFAOYSA-N 2,6-dimorpholin-4-ylpyrimidine-4-carboxylic acid Chemical compound N=1C(C(=O)O)=CC(N2CCOCC2)=NC=1N1CCOCC1 PLTAUCRWFSTPNT-UHFFFAOYSA-N 0.000 description 1
• AWYMBPHVOBHWMZ-UHFFFAOYSA-N 2-(2-oxo-1h-pyridin-4-yl)-n-(6,7,8,9-tetrahydro-5h-benzo[7]annulen-6-yl)-3h-benzimidazole-5-carboxamide Chemical compound C1=NC(O)=CC(C=2NC3=CC=C(C=C3N=2)C(=O)NC2CC3=CC=CC=C3CCC2)=C1 AWYMBPHVOBHWMZ-UHFFFAOYSA-N 0.000 description 1
• SIXCBDXPUAHUHC-UHFFFAOYSA-N 2-(4-cyanophenyl)-n-(6,7,8,9-tetrahydro-5h-benzo[7]annulen-6-yl)-3h-benzimidazole-5-carboxamide Chemical compound C1CCC2=CC=CC=C2CC1NC(=O)C(C=C1N=2)=CC=C1NC=2C1=CC=C(C#N)C=C1 SIXCBDXPUAHUHC-UHFFFAOYSA-N 0.000 description 1
• JSFMLACRNIKKEY-UHFFFAOYSA-N 2-(4-methylpiperazin-1-yl)-n-(6,7,8,9-tetrahydro-5h-benzo[7]annulen-6-yl)pyridine-4-carboxamide Chemical compound C1CN(C)CCN1C1=CC(C(=O)NC2CC3=CC=CC=C3CCC2)=CC=N1 JSFMLACRNIKKEY-UHFFFAOYSA-N 0.000 description 1
• QSOHSDWPMBYVFX-UHFFFAOYSA-N 2-(dimethylamino)-n-(6,7,8,9-tetrahydro-5h-benzo[7]annulen-6-yl)pyridine-4-carboxamide Chemical compound C1=NC(N(C)C)=CC(C(=O)NC2CC3=CC=CC=C3CCC2)=C1 QSOHSDWPMBYVFX-UHFFFAOYSA-N 0.000 description 1
• OXQGTIUCKGYOAA-UHFFFAOYSA-N 2-Ethylbutanoic acid Chemical compound CCC(CC)C(O)=O OXQGTIUCKGYOAA-UHFFFAOYSA-N 0.000 description 1
• QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
• UZSAQBDSLGCAGH-UHFFFAOYSA-N 2-amino-6-chloro-n-(6,7,8,9-tetrahydro-5h-benzo[7]annulen-6-yl)pyridine-3-carboxamide Chemical compound NC1=NC(Cl)=CC=C1C(=O)NC1CC2=CC=CC=C2CCC1 UZSAQBDSLGCAGH-UHFFFAOYSA-N 0.000 description 1
• UZSAQBDSLGCAGH-ZDUSSCGKSA-N 2-amino-6-chloro-n-[(6s)-6,7,8,9-tetrahydro-5h-benzo[7]annulen-6-yl]pyridine-3-carboxamide Chemical compound NC1=NC(Cl)=CC=C1C(=O)N[C@@H]1CC2=CC=CC=C2CCC1 UZSAQBDSLGCAGH-ZDUSSCGKSA-N 0.000 description 1
• RWTFUGCFQSOLLQ-UHFFFAOYSA-N 2-amino-n-(6,7,8,9-tetrahydro-5h-benzo[7]annulen-6-yl)pyridine-3-carboxamide;hydrochloride Chemical compound Cl.NC1=NC=CC=C1C(=O)NC1CC2=CC=CC=C2CCC1 RWTFUGCFQSOLLQ-UHFFFAOYSA-N 0.000 description 1
• TYZKYCRUUSKWDL-UHFFFAOYSA-N 2-anilino-n-(6,7,8,9-tetrahydro-5h-benzo[7]annulen-6-yl)pyrimidine-5-carboxamide Chemical compound C1CCC2=CC=CC=C2CC1NC(=O)C(C=N1)=CN=C1NC1=CC=CC=C1 TYZKYCRUUSKWDL-UHFFFAOYSA-N 0.000 description 1
• 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
• 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
• UVOKWCQPJDLHJO-UHFFFAOYSA-N 2-chloro-4-fluoro-n-(6,7,8,9-tetrahydro-5h-benzo[7]annulen-6-yl)benzamide Chemical compound ClC1=CC(F)=CC=C1C(=O)NC1CC2=CC=CC=C2CCC1 UVOKWCQPJDLHJO-UHFFFAOYSA-N 0.000 description 1
• VHCKWZQFSRFWAW-UHFFFAOYSA-N 2-chloro-5-(methanesulfonamido)-n-(6,7,8,9-tetrahydro-5h-benzo[7]annulen-6-yl)benzamide Chemical compound CS(=O)(=O)NC1=CC=C(Cl)C(C(=O)NC2CC3=CC=CC=C3CCC2)=C1 VHCKWZQFSRFWAW-UHFFFAOYSA-N 0.000 description 1
• IIQJVQXVXIIQOC-UHFFFAOYSA-N 2-chloro-6-methyl-n-(6,7,8,9-tetrahydro-5h-benzo[7]annulen-6-yl)pyridine-3-carboxamide Chemical compound ClC1=NC(C)=CC=C1C(=O)NC1CC2=CC=CC=C2CCC1 IIQJVQXVXIIQOC-UHFFFAOYSA-N 0.000 description 1
• UNCIANYTKCSOOE-UHFFFAOYSA-N 2-ethyl-5-methyl-n-(6,7,8,9-tetrahydro-5h-benzo[7]annulen-6-yl)pyrazole-3-carboxamide Chemical compound CCN1N=C(C)C=C1C(=O)NC1CC2=CC=CC=C2CCC1 UNCIANYTKCSOOE-UHFFFAOYSA-N 0.000 description 1
• 125000006022 2-methyl-2-propenyl group Chemical group 0.000 description 1
• GZHWABCBKGMLIE-UHFFFAOYSA-N 2-methyl-3h-benzimidazole-5-carboxylic acid Chemical compound C1=C(C(O)=O)C=C2NC(C)=NC2=C1 GZHWABCBKGMLIE-UHFFFAOYSA-N 0.000 description 1
• REKJPVUFKQYMHW-UHFFFAOYSA-N 2-methyl-4-(trifluoromethyl)-1,3-thiazole-5-carboxylic acid Chemical compound CC1=NC(C(F)(F)F)=C(C(O)=O)S1 REKJPVUFKQYMHW-UHFFFAOYSA-N 0.000 description 1
• ICPYGOILDYAPJT-UHFFFAOYSA-N 2-methyl-n-(6,7,8,9-tetrahydro-5h-benzo[7]annulen-6-yl)-1,3-thiazole-5-carboxamide Chemical compound S1C(C)=NC=C1C(=O)NC1CC2=CC=CC=C2CCC1 ICPYGOILDYAPJT-UHFFFAOYSA-N 0.000 description 1
• ATYJEDSDZMEHAX-UHFFFAOYSA-N 2-methyl-n-(6,7,8,9-tetrahydro-5h-benzo[7]annulen-6-yl)pyrimidine-5-carboxamide Chemical compound C1=NC(C)=NC=C1C(=O)NC1CC2=CC=CC=C2CCC1 ATYJEDSDZMEHAX-UHFFFAOYSA-N 0.000 description 1
• AVYNORNFILBJTK-KRWDZBQOSA-N 2-methyl-n-[(6s)-6,7,8,9-tetrahydro-5h-benzo[7]annulen-6-yl]-3h-benzimidazole-5-carboxamide Chemical compound C1CCC2=CC=CC=C2C[C@H]1NC(=O)C1=CC=C2N=C(C)NC2=C1 AVYNORNFILBJTK-KRWDZBQOSA-N 0.000 description 1
• TTXKXKNOVOIZFU-UHFFFAOYSA-N 2-morpholin-4-yl-n-(6,7,8,9-tetrahydro-5h-benzo[7]annulen-6-yl)pyrimidine-5-carboxamide Chemical compound C1CCC2=CC=CC=C2CC1NC(=O)C(C=N1)=CN=C1N1CCOCC1 TTXKXKNOVOIZFU-UHFFFAOYSA-N 0.000 description 1
• 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
• 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
• BXYJXZRUQRQOJY-UHFFFAOYSA-N 3,5-dimethyl-n-(6,7,8,9-tetrahydro-5h-benzo[7]annulen-6-yl)-1h-pyrazole-4-carboxamide Chemical compound CC1=NNC(C)=C1C(=O)NC1CC2=CC=CC=C2CCC1 BXYJXZRUQRQOJY-UHFFFAOYSA-N 0.000 description 1
• XSNRJGBVBLNFGZ-UHFFFAOYSA-N 3,6-dichloro-n-(6,7,8,9-tetrahydro-5h-benzo[7]annulen-6-yl)pyridine-2-carboxamide Chemical compound ClC1=CC=C(Cl)C(C(=O)NC2CC3=CC=CC=C3CCC2)=N1 XSNRJGBVBLNFGZ-UHFFFAOYSA-N 0.000 description 1
• BIYWSHHEDNYIAT-UHFFFAOYSA-N 3-(4-methylpiperazin-1-yl)-n-(6,7,8,9-tetrahydro-5h-benzo[7]annulen-6-yl)benzamide Chemical compound C1CN(C)CCN1C1=CC=CC(C(=O)NC2CC3=CC=CC=C3CCC2)=C1 BIYWSHHEDNYIAT-UHFFFAOYSA-N 0.000 description 1
• YCUVGLPKWLTUSW-UHFFFAOYSA-N 3-(benzylamino)-6-chloropyridine-2-carboxylic acid Chemical compound OC(=O)C1=NC(Cl)=CC=C1NCC1=CC=CC=C1 YCUVGLPKWLTUSW-UHFFFAOYSA-N 0.000 description 1
• WEDZOVCXNNWMAX-IBGZPJMESA-N 3-(dimethylamino)-4-methyl-n-[(6s)-6,7,8,9-tetrahydro-5h-benzo[7]annulen-6-yl]benzamide Chemical compound C1=C(C)C(N(C)C)=CC(C(=O)N[C@@H]2CC3=CC=CC=C3CCC2)=C1 WEDZOVCXNNWMAX-IBGZPJMESA-N 0.000 description 1
• GWAMHTTZNLKTIV-UHFFFAOYSA-N 3-(methanesulfonamido)-2-methyl-n-(6,7,8,9-tetrahydro-5h-benzo[7]annulen-6-yl)benzamide Chemical compound CC1=C(NS(C)(=O)=O)C=CC=C1C(=O)NC1CC2=CC=CC=C2CCC1 GWAMHTTZNLKTIV-UHFFFAOYSA-N 0.000 description 1
• KUFORLRAFWDSHO-SFHVURJKSA-N 3-(methanesulfonamido)-4-methyl-n-[(6s)-6,7,8,9-tetrahydro-5h-benzo[7]annulen-6-yl]benzamide Chemical compound C1=C(NS(C)(=O)=O)C(C)=CC=C1C(=O)N[C@@H]1CC2=CC=CC=C2CCC1 KUFORLRAFWDSHO-SFHVURJKSA-N 0.000 description 1
• QGLUZQRTRKFTCP-UHFFFAOYSA-N 3-(methanesulfonamido)-n-(6,7,8,9-tetrahydro-5h-benzo[7]annulen-6-yl)benzamide Chemical compound CS(=O)(=O)NC1=CC=CC(C(=O)NC2CC3=CC=CC=C3CCC2)=C1 QGLUZQRTRKFTCP-UHFFFAOYSA-N 0.000 description 1
• BAYYGGZCXHSCBM-UHFFFAOYSA-N 3-(methanesulfonamido)pyridine-2-carboxylic acid Chemical compound CS(=O)(=O)NC1=CC=CN=C1C(O)=O BAYYGGZCXHSCBM-UHFFFAOYSA-N 0.000 description 1
• IPGHOIXQBNZIBN-UHFFFAOYSA-N 3-amino-5-methyl-n-(6,7,8,9-tetrahydro-5h-benzo[7]annulen-6-yl)pyrazine-2-carboxamide Chemical compound NC1=NC(C)=CN=C1C(=O)NC1CC2=CC=CC=C2CCC1 IPGHOIXQBNZIBN-UHFFFAOYSA-N 0.000 description 1
• IPGHOIXQBNZIBN-AWEZNQCLSA-N 3-amino-5-methyl-n-[(6s)-6,7,8,9-tetrahydro-5h-benzo[7]annulen-6-yl]pyrazine-2-carboxamide Chemical compound NC1=NC(C)=CN=C1C(=O)N[C@@H]1CC2=CC=CC=C2CCC1 IPGHOIXQBNZIBN-AWEZNQCLSA-N 0.000 description 1
• UXQXSWMDPHMVAE-UHFFFAOYSA-N 3-amino-n-(6,7,8,9-tetrahydro-5h-benzo[7]annulen-6-yl)pyridine-2-carboxamide Chemical compound NC1=CC=CN=C1C(=O)NC1CC2=CC=CC=C2CCC1 UXQXSWMDPHMVAE-UHFFFAOYSA-N 0.000 description 1
• ZAGZIOYVEIDDJA-UHFFFAOYSA-N 3-aminopyrazine-2-carboxylic acid Chemical compound NC1=NC=CN=C1C(O)=O ZAGZIOYVEIDDJA-UHFFFAOYSA-N 0.000 description 1
• 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
• AQCRFDKOKZGTDE-UHFFFAOYSA-N 3-methoxyquinoline Chemical compound C1=CC=CC2=CC(OC)=CN=C21 AQCRFDKOKZGTDE-UHFFFAOYSA-N 0.000 description 1
• JBEDUMANIZZAJZ-UHFFFAOYSA-N 3-methyl-2-pyridin-4-yl-1h-indole-5-carboxylic acid Chemical compound N1C2=CC=C(C(O)=O)C=C2C(C)=C1C1=CC=NC=C1 JBEDUMANIZZAJZ-UHFFFAOYSA-N 0.000 description 1
• MRYZUTXZUJNGPT-UHFFFAOYSA-N 3-methyl-n-(6,7,8,9-tetrahydro-5h-benzo[7]annulen-6-yl)-1,2-oxazole-4-carboxamide Chemical compound CC1=NOC=C1C(=O)NC1CC2=CC=CC=C2CCC1 MRYZUTXZUJNGPT-UHFFFAOYSA-N 0.000 description 1
• DSDOJEPISLTCQZ-UHFFFAOYSA-N 3-morpholin-4-yl-n-(6,7,8,9-tetrahydro-5h-benzo[7]annulen-6-yl)benzamide Chemical compound C1CCC2=CC=CC=C2CC1NC(=O)C(C=1)=CC=CC=1N1CCOCC1 DSDOJEPISLTCQZ-UHFFFAOYSA-N 0.000 description 1
• XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
• XXUINTKUSWFEHM-UHFFFAOYSA-N 3-piperidin-1-yl-n-(6,7,8,9-tetrahydro-5h-benzo[7]annulen-6-yl)benzamide Chemical compound C1CCC2=CC=CC=C2CC1NC(=O)C(C=1)=CC=CC=1N1CCCCC1 XXUINTKUSWFEHM-UHFFFAOYSA-N 0.000 description 1
• FFSCORVBTIHXLQ-UHFFFAOYSA-N 4-(benzylamino)-n-(6,7,8,9-tetrahydro-5h-benzo[7]annulen-6-yl)pyridine-2-carboxamide Chemical compound C1CCC2=CC=CC=C2CC1NC(=O)C(N=CC=1)=CC=1NCC1=CC=CC=C1 FFSCORVBTIHXLQ-UHFFFAOYSA-N 0.000 description 1
• TYAKXNHFMATCHA-UHFFFAOYSA-N 4-amino-2-ethylsulfanylpyrimidine-5-carboxylic acid Chemical compound CCSC1=NC=C(C(O)=O)C(N)=N1 TYAKXNHFMATCHA-UHFFFAOYSA-N 0.000 description 1
• PYQZXIRINQJKRO-UHFFFAOYSA-N 4-amino-2-methyl-n-(6,7,8,9-tetrahydro-5h-benzo[7]annulen-6-yl)pyrimidine-5-carboxamide Chemical compound NC1=NC(C)=NC=C1C(=O)NC1CC2=CC=CC=C2CCC1 PYQZXIRINQJKRO-UHFFFAOYSA-N 0.000 description 1
• PPFKNENIHJNQOT-UHFFFAOYSA-N 4-amino-2-pyridin-2-ylpyrimidine-5-carboxylic acid Chemical compound C1=C(C(O)=O)C(N)=NC(C=2N=CC=CC=2)=N1 PPFKNENIHJNQOT-UHFFFAOYSA-N 0.000 description 1
• WOXWWNLYVJKNTC-UHFFFAOYSA-N 4-amino-2-pyridin-3-ylpyrimidine-5-carboxylic acid Chemical compound C1=C(C(O)=O)C(N)=NC(C=2C=NC=CC=2)=N1 WOXWWNLYVJKNTC-UHFFFAOYSA-N 0.000 description 1
• YERXFQDSPYCZOP-UHFFFAOYSA-N 4-amino-2-pyridin-4-ylpyrimidine-5-carboxylic acid Chemical compound C1=C(C(O)=O)C(N)=NC(C=2C=CN=CC=2)=N1 YERXFQDSPYCZOP-UHFFFAOYSA-N 0.000 description 1
• NDMSPOAOOOBRFX-UHFFFAOYSA-N 4-amino-n-(6,7,8,9-tetrahydro-5h-benzo[7]annulen-6-yl)pyridine-2-carboxamide Chemical compound NC1=CC=NC(C(=O)NC2CC3=CC=CC=C3CCC2)=C1 NDMSPOAOOOBRFX-UHFFFAOYSA-N 0.000 description 1
• BQJXVWAPUNGYLE-UHFFFAOYSA-N 4-chloro-2-methyl-n-(6,7,8,9-tetrahydro-5h-benzo[7]annulen-6-yl)benzamide Chemical compound CC1=CC(Cl)=CC=C1C(=O)NC1CC2=CC=CC=C2CCC1 BQJXVWAPUNGYLE-UHFFFAOYSA-N 0.000 description 1
• FVEOXAFUUBAKAX-UHFFFAOYSA-N 4-chloro-3-(methanesulfonamido)-n-(6,7,8,9-tetrahydro-5h-benzo[7]annulen-6-yl)benzamide Chemical compound C1=C(Cl)C(NS(=O)(=O)C)=CC(C(=O)NC2CC3=CC=CC=C3CCC2)=C1 FVEOXAFUUBAKAX-UHFFFAOYSA-N 0.000 description 1
• VRDRRSMQGYRBOE-UHFFFAOYSA-N 4-chloro-3-sulfamoyl-n-(6,7,8,9-tetrahydro-5h-benzo[7]annulen-6-yl)benzamide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(=O)NC2CC3=CC=CC=C3CCC2)=C1 VRDRRSMQGYRBOE-UHFFFAOYSA-N 0.000 description 1
• NMQMBYKXKVBDBB-UHFFFAOYSA-N 4-chloro-n-(6,7,8,9-tetrahydro-5h-benzo[7]annulen-6-yl)pyridine-2-carboxamide Chemical compound ClC1=CC=NC(C(=O)NC2CC3=CC=CC=C3CCC2)=C1 NMQMBYKXKVBDBB-UHFFFAOYSA-N 0.000 description 1
• 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
• WXOCEZLGICKXHB-UHFFFAOYSA-N 4-fluoro-n-(5-hydroxy-6,7,8,9-tetrahydro-5h-benzo[7]annulen-6-yl)benzamide Chemical compound C1CCC2=CC=CC=C2C(O)C1NC(=O)C1=CC=C(F)C=C1 WXOCEZLGICKXHB-UHFFFAOYSA-N 0.000 description 1
• UFICWIPCNTXNPV-UHFFFAOYSA-N 4-methyl-2-phenyl-n-(6,7,8,9-tetrahydro-5h-benzo[7]annulen-6-yl)-1,3-thiazole-5-carboxamide Chemical compound S1C(C(=O)NC2CC3=CC=CC=C3CCC2)=C(C)N=C1C1=CC=CC=C1 UFICWIPCNTXNPV-UHFFFAOYSA-N 0.000 description 1
• LUCDEDKQTSZEEJ-UHFFFAOYSA-N 4-methyl-3-(methylamino)-n-(6,7,8,9-tetrahydro-5h-benzo[7]annulen-6-yl)benzamide Chemical compound C1=C(C)C(NC)=CC(C(=O)NC2CC3=CC=CC=C3CCC2)=C1 LUCDEDKQTSZEEJ-UHFFFAOYSA-N 0.000 description 1
• GFSWTMBPGWKMGR-UHFFFAOYSA-N 4-methyl-n-(6,7,8,9-tetrahydro-5h-benzo[7]annulen-6-yl)-1,3-thiazole-5-carboxamide Chemical compound N1=CSC(C(=O)NC2CC3=CC=CC=C3CCC2)=C1C GFSWTMBPGWKMGR-UHFFFAOYSA-N 0.000 description 1
• VZNOMUNUTAENIA-UHFFFAOYSA-N 4-methyl-n-(6,7,8,9-tetrahydro-5h-benzo[7]annulen-6-yl)thiadiazole-5-carboxamide Chemical compound N1=NSC(C(=O)NC2CC3=CC=CC=C3CCC2)=C1C VZNOMUNUTAENIA-UHFFFAOYSA-N 0.000 description 1
• 108020005029 5' Flanking Region Proteins 0.000 description 1
• MNBYREKBGYELMY-UHFFFAOYSA-N 5-(4-methylpiperazin-1-yl)-n-(6,7,8,9-tetrahydro-5h-benzo[7]annulen-6-yl)pyridine-3-carboxamide Chemical compound C1CN(C)CCN1C1=CN=CC(C(=O)NC2CC3=CC=CC=C3CCC2)=C1 MNBYREKBGYELMY-UHFFFAOYSA-N 0.000 description 1
• QTCWUUWLTMXGMP-UHFFFAOYSA-N 5-amino-1-phenyl-n-(6,7,8,9-tetrahydro-5h-benzo[7]annulen-6-yl)pyrazole-4-carboxamide Chemical compound NC1=C(C(=O)NC2CC3=CC=CC=C3CCC2)C=NN1C1=CC=CC=C1 QTCWUUWLTMXGMP-UHFFFAOYSA-N 0.000 description 1
• ZBWGONUZQCSCOO-UHFFFAOYSA-N 5-methyl-1-phenyl-n-(6,7,8,9-tetrahydro-5h-benzo[7]annulen-6-yl)pyrazole-4-carboxamide Chemical compound CC1=C(C(=O)NC2CC3=CC=CC=C3CCC2)C=NN1C1=CC=CC=C1 ZBWGONUZQCSCOO-UHFFFAOYSA-N 0.000 description 1
• MHPQEFNOFDHLOZ-UHFFFAOYSA-N 5-methyl-n-(6,7,8,9-tetrahydro-5h-benzo[7]annulen-6-yl)-1,2-oxazole-3-carboxamide Chemical compound O1C(C)=CC(C(=O)NC2CC3=CC=CC=C3CCC2)=N1 MHPQEFNOFDHLOZ-UHFFFAOYSA-N 0.000 description 1
• CODFTUHRZPVULK-UHFFFAOYSA-N 5-methyl-n-(6,7,8,9-tetrahydro-5h-benzo[7]annulen-6-yl)pyridine-3-carboxamide Chemical compound CC1=CN=CC(C(=O)NC2CC3=CC=CC=C3CCC2)=C1 CODFTUHRZPVULK-UHFFFAOYSA-N 0.000 description 1
• CNNQEDSBTWAYCM-UHFFFAOYSA-N 5-morpholin-4-yl-n-(6,7,8,9-tetrahydro-5h-benzo[7]annulen-6-yl)pyridine-3-carboxamide Chemical compound C1CCC2=CC=CC=C2CC1NC(=O)C(C=1)=CN=CC=1N1CCOCC1 CNNQEDSBTWAYCM-UHFFFAOYSA-N 0.000 description 1
• VYQAJXYTKNFCNH-UHFFFAOYSA-N 5-pyrrolidin-1-yl-n-(6,7,8,9-tetrahydro-5h-benzo[7]annulen-6-yl)pyridine-3-carboxamide Chemical compound C1CCC2=CC=CC=C2CC1NC(=O)C(C=1)=CN=CC=1N1CCCC1 VYQAJXYTKNFCNH-UHFFFAOYSA-N 0.000 description 1
• KWHUHTFXMNQHAA-UHFFFAOYSA-N 6,7,8,9-tetrahydrobenzo[7]annulen-5-one Chemical compound O=C1CCCCC2=CC=CC=C12 KWHUHTFXMNQHAA-UHFFFAOYSA-N 0.000 description 1
• FQTGDFOQINANSY-UHFFFAOYSA-N 6-(4-methylpiperazin-1-yl)pyridine-2-carboxylic acid Chemical compound C1CN(C)CCN1C1=CC=CC(C(O)=O)=N1 FQTGDFOQINANSY-UHFFFAOYSA-N 0.000 description 1
• WBAXIPQLWQZRPJ-UHFFFAOYSA-N 6-(benzylamino)-3-chloropyridine-2-carboxylic acid Chemical compound C1=C(Cl)C(C(=O)O)=NC(NCC=2C=CC=CC=2)=C1 WBAXIPQLWQZRPJ-UHFFFAOYSA-N 0.000 description 1
• MKJFYGPEYVYATB-UHFFFAOYSA-N 6-(dimethylamino)-n-(6,7,8,9-tetrahydro-5h-benzo[7]annulen-6-yl)pyridine-3-carboxamide Chemical compound C1=NC(N(C)C)=CC=C1C(=O)NC1CC2=CC=CC=C2CCC1 MKJFYGPEYVYATB-UHFFFAOYSA-N 0.000 description 1
• MKJFYGPEYVYATB-KRWDZBQOSA-N 6-(dimethylamino)-n-[(6s)-6,7,8,9-tetrahydro-5h-benzo[7]annulen-6-yl]pyridine-3-carboxamide Chemical compound C1=NC(N(C)C)=CC=C1C(=O)N[C@@H]1CC2=CC=CC=C2CCC1 MKJFYGPEYVYATB-KRWDZBQOSA-N 0.000 description 1
• SXAGWZRPBGKENW-UHFFFAOYSA-N 6-(methylamino)-n-(6,7,8,9-tetrahydro-5h-benzo[7]annulen-6-yl)pyrazine-2-carboxamide Chemical compound CNC1=CN=CC(C(=O)NC2CC3=CC=CC=C3CCC2)=N1 SXAGWZRPBGKENW-UHFFFAOYSA-N 0.000 description 1
• UOXTZLUWLJREAL-UHFFFAOYSA-N 6-chloro-n-(6,7,8,9-tetrahydro-5h-benzo[7]annulen-6-yl)pyridine-3-carboxamide Chemical compound C1=NC(Cl)=CC=C1C(=O)NC1CC2=CC=CC=C2CCC1 UOXTZLUWLJREAL-UHFFFAOYSA-N 0.000 description 1
• PBCLZAZIBXXYDP-UHFFFAOYSA-N 6-ethynyl-n-(6,7,8,9-tetrahydro-5h-benzo[7]annulen-6-yl)pyridine-3-carboxamide Chemical compound C1CCC2=CC=CC=C2CC1NC(=O)C1=CC=C(C#C)N=C1 PBCLZAZIBXXYDP-UHFFFAOYSA-N 0.000 description 1
• JLMZPGGAMGYNLG-UHFFFAOYSA-N 6-methoxy-n-(6,7,8,9-tetrahydro-5h-benzo[7]annulen-6-yl)pyridine-3-carboxamide Chemical compound C1=NC(OC)=CC=C1C(=O)NC1CC2=CC=CC=C2CCC1 JLMZPGGAMGYNLG-UHFFFAOYSA-N 0.000 description 1
• OPOHQRLFBBDBIY-UHFFFAOYSA-N 6-methyl-2-oxo-n-(6,7,8,9-tetrahydro-5h-benzo[7]annulen-6-yl)-1h-pyridine-3-carboxamide Chemical compound OC1=NC(C)=CC=C1C(=O)NC1CC2=CC=CC=C2CCC1 OPOHQRLFBBDBIY-UHFFFAOYSA-N 0.000 description 1
• RDAMTQOBSKYTCW-UHFFFAOYSA-N 6-methyl-n-(6,7,8,9-tetrahydro-5h-benzo[7]annulen-6-yl)pyridine-3-carboxamide Chemical compound C1=NC(C)=CC=C1C(=O)NC1CC2=CC=CC=C2CCC1 RDAMTQOBSKYTCW-UHFFFAOYSA-N 0.000 description 1
• NQQQRFLSXGQDMD-UHFFFAOYSA-N 6-morpholin-4-yl-n-(6,7,8,9-tetrahydro-5h-benzo[7]annulen-6-yl)pyridine-3-carboxamide Chemical compound C1CCC2=CC=CC=C2CC1NC(=O)C(C=N1)=CC=C1N1CCOCC1 NQQQRFLSXGQDMD-UHFFFAOYSA-N 0.000 description 1
• BLXJFNFGLYABHQ-UHFFFAOYSA-N 6-pyrrolidin-1-yl-n-(6,7,8,9-tetrahydro-5h-benzo[7]annulen-6-yl)pyrazine-2-carboxamide Chemical compound C1CCC2=CC=CC=C2CC1NC(=O)C(N=1)=CN=CC=1N1CCCC1 BLXJFNFGLYABHQ-UHFFFAOYSA-N 0.000 description 1
• DSZZLXXMRLDWRD-UHFFFAOYSA-N 6-pyrrolidin-1-yl-n-(6,7,8,9-tetrahydro-5h-benzo[7]annulen-6-yl)pyridine-2-carboxamide Chemical compound C1CCC2=CC=CC=C2CC1NC(=O)C(N=1)=CC=CC=1N1CCCC1 DSZZLXXMRLDWRD-UHFFFAOYSA-N 0.000 description 1
• FUXGIWUFWCCHHY-IBGZPJMESA-N 6-pyrrolidin-1-yl-n-[(6s)-6,7,8,9-tetrahydro-5h-benzo[7]annulen-6-yl]pyridine-3-carboxamide Chemical compound N([C@@H]1CC2=CC=CC=C2CCC1)C(=O)C(C=N1)=CC=C1N1CCCC1 FUXGIWUFWCCHHY-IBGZPJMESA-N 0.000 description 1
• ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
• 239000005541 ACE inhibitor Substances 0.000 description 1
• 102000007469 Actins Human genes 0.000 description 1
• 108010085238 Actins Proteins 0.000 description 1
• 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
• 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
• 102100034604 Angiopoietin-like protein 8 Human genes 0.000 description 1
• 238000013258 ApoE Receptor knockout mouse model Methods 0.000 description 1
• 206010003225 Arteriospasm coronary Diseases 0.000 description 1
• 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
• 239000005711 Benzoic acid Substances 0.000 description 1
• WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
• 238000011740 C57BL/6 mouse Methods 0.000 description 1
• ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
• 235000003913 Coccoloba uvifera Nutrition 0.000 description 1
• 229920002261 Corn starch Polymers 0.000 description 1
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
• ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
• RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
• FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
• IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 1
• 241000854350 Enicospilus group Species 0.000 description 1
• 102000004190 Enzymes Human genes 0.000 description 1
• 108090000790 Enzymes Proteins 0.000 description 1
• 108090000331 Firefly luciferases Proteins 0.000 description 1
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
• 239000007821 HATU Substances 0.000 description 1
• 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
• 241000282412 Homo Species 0.000 description 1
• 101000924544 Homo sapiens Angiopoietin-like protein 8 Proteins 0.000 description 1
• 108010044467 Isoenzymes Proteins 0.000 description 1
• 102000007330 LDL Lipoproteins Human genes 0.000 description 1
• 108010007622 LDL Lipoproteins Proteins 0.000 description 1
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
• 239000004472 Lysine Substances 0.000 description 1
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
• 241000124008 Mammalia Species 0.000 description 1
• 229930195725 Mannitol Natural products 0.000 description 1
• 229920000881 Modified starch Polymers 0.000 description 1
• 241000699666 Mus <mouse, genus> Species 0.000 description 1
• 101100080274 Mus musculus Nos3 gene Proteins 0.000 description 1
• 239000007832 Na2SO4 Substances 0.000 description 1
• PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
• 108010075520 Nitric Oxide Synthase Type III Proteins 0.000 description 1
• GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
• 239000000020 Nitrocellulose Substances 0.000 description 1
• NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 1
• QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
• 208000030831 Peripheral arterial occlusive disease Diseases 0.000 description 1
• 108010050276 Protein Kinase C-alpha Proteins 0.000 description 1
• 108010078137 Protein Kinase C-epsilon Proteins 0.000 description 1
• 102100024924 Protein kinase C alpha type Human genes 0.000 description 1
• 102100037339 Protein kinase C epsilon type Human genes 0.000 description 1
• 240000008976 Pterocarpus marsupium Species 0.000 description 1
• 229940123934 Reductase inhibitor Drugs 0.000 description 1
• RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
• UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
• 208000005392 Spasm Diseases 0.000 description 1
• 229920002472 Starch Polymers 0.000 description 1
• 108091081024 Start codon Proteins 0.000 description 1
• 235000021355 Stearic acid Nutrition 0.000 description 1
• KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
• 229930006000 Sucrose Natural products 0.000 description 1
• FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
• GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
• 229930003268 Vitamin C Natural products 0.000 description 1
• 235000011054 acetic acid Nutrition 0.000 description 1
• 230000009471 action Effects 0.000 description 1
• 230000001154 acute effect Effects 0.000 description 1
• 125000002015 acyclic group Chemical group 0.000 description 1
• 239000001361 adipic acid Substances 0.000 description 1
• 235000011037 adipic acid Nutrition 0.000 description 1
• 230000002776 aggregation Effects 0.000 description 1
• 238000004220 aggregation Methods 0.000 description 1
• 229910052783 alkali metal Inorganic materials 0.000 description 1
• 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
• 125000004183 alkoxy alkyl group Chemical group 0.000 description 1
• 125000005082 alkoxyalkenyl group Chemical group 0.000 description 1
• 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
• 239000002160 alpha blocker Substances 0.000 description 1
• 229940124308 alpha-adrenoreceptor antagonist Drugs 0.000 description 1
• BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
• 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
• 150000001408 amides Chemical class 0.000 description 1
• 229910021529 ammonia Inorganic materials 0.000 description 1
• 150000003863 ammonium salts Chemical class 0.000 description 1
• 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
• 238000005349 anion exchange Methods 0.000 description 1
• 230000003276 anti-hypertensive effect Effects 0.000 description 1
• 239000003963 antioxidant agent Substances 0.000 description 1
• 235000006708 antioxidants Nutrition 0.000 description 1
• 239000008346 aqueous phase Substances 0.000 description 1
• 239000007864 aqueous solution Substances 0.000 description 1
• 229960003121 arginine Drugs 0.000 description 1
• 150000001491 aromatic compounds Chemical class 0.000 description 1
• 125000005018 aryl alkenyl group Chemical group 0.000 description 1
• 125000003710 aryl alkyl group Chemical group 0.000 description 1
• 239000011668 ascorbic acid Substances 0.000 description 1
• 235000010323 ascorbic acid Nutrition 0.000 description 1
• 229960005070 ascorbic acid Drugs 0.000 description 1
• 239000012298 atmosphere Substances 0.000 description 1
• 230000001746 atrial effect Effects 0.000 description 1
• 235000010233 benzoic acid Nutrition 0.000 description 1
• 239000002876 beta blocker Substances 0.000 description 1
• 229940097320 beta blocking agent Drugs 0.000 description 1
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
• 239000011230 binding agent Substances 0.000 description 1
• 230000000975 bioactive effect Effects 0.000 description 1
• 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 description 1
• 230000017531 blood circulation Effects 0.000 description 1
• 210000001772 blood platelet Anatomy 0.000 description 1
• 230000037396 body weight Effects 0.000 description 1
• GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
• 239000007853 buffer solution Substances 0.000 description 1
• KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
• 125000005569 butenylene group Chemical group 0.000 description 1
• 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 159000000007 calcium salts Chemical class 0.000 description 1
• 239000004202 carbamide Substances 0.000 description 1
• 150000001718 carbodiimides Chemical class 0.000 description 1
• 229910002091 carbon monoxide Inorganic materials 0.000 description 1
• 239000003054 catalyst Substances 0.000 description 1
• 238000005341 cation exchange Methods 0.000 description 1
• 238000004113 cell culture Methods 0.000 description 1
• 230000008859 change Effects 0.000 description 1
• 239000003153 chemical reaction reagent Substances 0.000 description 1
• 230000001713 cholinergic effect Effects 0.000 description 1
• 230000004087 circulation Effects 0.000 description 1
• 239000011248 coating agent Substances 0.000 description 1
• 230000002508 compound effect Effects 0.000 description 1
• 238000004590 computer program Methods 0.000 description 1
• 238000007796 conventional method Methods 0.000 description 1
• 238000001816 cooling Methods 0.000 description 1
• 229920001577 copolymer Polymers 0.000 description 1
• 239000008120 corn starch Substances 0.000 description 1
• 230000008878 coupling Effects 0.000 description 1
• 238000010168 coupling process Methods 0.000 description 1
• 239000012043 crude product Substances 0.000 description 1
• 238000002425 crystallisation Methods 0.000 description 1
• 230000008025 crystallization Effects 0.000 description 1
• 125000004122 cyclic group Chemical group 0.000 description 1
• 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
• 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
• 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
• 125000000522 cyclooctenyl group Chemical group C1(=CCCCCCC1)* 0.000 description 1
• 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
• 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
• 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
• 210000004292 cytoskeleton Anatomy 0.000 description 1
• 238000006264 debenzylation reaction Methods 0.000 description 1
• 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 230000007812 deficiency Effects 0.000 description 1
• 230000008021 deposition Effects 0.000 description 1
• 238000001212 derivatisation Methods 0.000 description 1
• 238000001514 detection method Methods 0.000 description 1
• 238000011161 development Methods 0.000 description 1
• WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 1
• HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
• 239000003085 diluting agent Substances 0.000 description 1
• 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
• 239000007884 disintegrant Substances 0.000 description 1
• 239000002552 dosage form Substances 0.000 description 1
• 238000001035 drying Methods 0.000 description 1
• 230000004064 dysfunction Effects 0.000 description 1
• 239000003995 emulsifying agent Substances 0.000 description 1
• 150000002148 esters Chemical class 0.000 description 1
• 229940011871 estrogen Drugs 0.000 description 1
• 239000000262 estrogen Substances 0.000 description 1
• JSQILTKCMONXJK-UHFFFAOYSA-N ethyl 5-(6,7,8,9-tetrahydro-5h-benzo[7]annulen-6-ylcarbamoyl)pyridine-2-carboxylate Chemical compound C1=NC(C(=O)OCC)=CC=C1C(=O)NC1CC2=CC=CC=C2CCC1 JSQILTKCMONXJK-UHFFFAOYSA-N 0.000 description 1
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
• 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
• 239000013613 expression plasmid Substances 0.000 description 1
• 239000000945 filler Substances 0.000 description 1
• 239000000706 filtrate Substances 0.000 description 1
• 235000003599 food sweetener Nutrition 0.000 description 1
• 239000012634 fragment Substances 0.000 description 1
• 239000001530 fumaric acid Substances 0.000 description 1
• 238000007306 functionalization reaction Methods 0.000 description 1
• 239000000174 gluconic acid Substances 0.000 description 1
• 235000012208 gluconic acid Nutrition 0.000 description 1
• 239000008103 glucose Substances 0.000 description 1
• 235000001727 glucose Nutrition 0.000 description 1
• 229940093915 gynecological organic acid Drugs 0.000 description 1
• 230000036541 health Effects 0.000 description 1
• 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
• 125000005549 heteroarylene group Chemical group 0.000 description 1
• 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 150000004677 hydrates Chemical class 0.000 description 1
• 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
• 238000005984 hydrogenation reaction Methods 0.000 description 1
• 125000005020 hydroxyalkenyl group Chemical group 0.000 description 1
• 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
• 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
• 238000010191 image analysis Methods 0.000 description 1
• 238000003384 imaging method Methods 0.000 description 1
• 238000000338 in vitro Methods 0.000 description 1
• 238000011534 incubation Methods 0.000 description 1
• 125000004129 indan-1-yl group Chemical group [H]C1=C([H])C([H])=C2C(=C1[H])C([H])([H])C([H])([H])C2([H])* 0.000 description 1
• 125000004130 indan-2-yl group Chemical group [H]C1=C([H])C([H])=C2C(=C1[H])C([H])([H])C([H])(*)C2([H])[H] 0.000 description 1
• 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
• 230000003993 interaction Effects 0.000 description 1
• 239000007927 intramuscular injection Substances 0.000 description 1
• 238000010255 intramuscular injection Methods 0.000 description 1
• 238000007912 intraperitoneal administration Methods 0.000 description 1
• 239000007928 intraperitoneal injection Substances 0.000 description 1
• 229960004903 invert sugar Drugs 0.000 description 1
• PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
• 229910052740 iodine Inorganic materials 0.000 description 1
• 239000011630 iodine Substances 0.000 description 1
• OWFXIOWLTKNBAP-UHFFFAOYSA-N isoamyl nitrite Chemical compound CC(C)CCON=O OWFXIOWLTKNBAP-UHFFFAOYSA-N 0.000 description 1
• 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
• 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
• 208000017169 kidney disease Diseases 0.000 description 1
• 239000008101 lactose Substances 0.000 description 1
• 210000005246 left atrium Anatomy 0.000 description 1
• 210000005240 left ventricle Anatomy 0.000 description 1
• 230000003902 lesion Effects 0.000 description 1
• 210000000265 leukocyte Anatomy 0.000 description 1
• 239000000314 lubricant Substances 0.000 description 1
• 238000003670 luciferase enzyme activity assay Methods 0.000 description 1
• 238000002961 luciferase induction Methods 0.000 description 1
• 239000006166 lysate Substances 0.000 description 1
• 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 description 1
• 159000000003 magnesium salts Chemical class 0.000 description 1
• VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
• 239000011976 maleic acid Substances 0.000 description 1
• 239000001630 malic acid Substances 0.000 description 1
• 235000011090 malic acid Nutrition 0.000 description 1
• 239000000594 mannitol Substances 0.000 description 1
• 235000010355 mannitol Nutrition 0.000 description 1
• 238000005259 measurement Methods 0.000 description 1
• 239000012528 membrane Substances 0.000 description 1
• 230000007334 memory performance Effects 0.000 description 1
• 239000002207 metabolite Substances 0.000 description 1
• 229940098779 methanesulfonic acid Drugs 0.000 description 1
• 235000019426 modified starch Nutrition 0.000 description 1
• 210000001616 monocyte Anatomy 0.000 description 1
• 125000002757 morpholinyl group Chemical group 0.000 description 1
• 230000004660 morphological change Effects 0.000 description 1
• 230000003562 morphometric effect Effects 0.000 description 1
• 238000013425 morphometry Methods 0.000 description 1
• 238000000465 moulding Methods 0.000 description 1
• 230000035772 mutation Effects 0.000 description 1
• LNOPIUAQISRISI-UHFFFAOYSA-N n'-hydroxy-2-propan-2-ylsulfonylethanimidamide Chemical compound CC(C)S(=O)(=O)CC(N)=NO LNOPIUAQISRISI-UHFFFAOYSA-N 0.000 description 1
• FQGZVTKZXXSXGW-UHFFFAOYSA-N n-(6,7,8,9-tetrahydro-5h-benzo[7]annulen-6-yl)-1h-indole-4-carboxamide Chemical compound C1CCC2=CC=CC=C2CC1NC(=O)C1=CC=CC2=C1C=CN2 FQGZVTKZXXSXGW-UHFFFAOYSA-N 0.000 description 1
• YNOIIQNXNVBFIP-UHFFFAOYSA-N n-(6,7,8,9-tetrahydro-5h-benzo[7]annulen-6-yl)-2h-benzotriazole-5-carboxamide Chemical compound C1CCC2=CC=CC=C2CC1NC(=O)C1=CC=C(NN=N2)C2=C1 YNOIIQNXNVBFIP-UHFFFAOYSA-N 0.000 description 1
• ISBRVCSGDWWGFN-UHFFFAOYSA-N n-(6,7,8,9-tetrahydro-5h-benzo[7]annulen-6-yl)-4-(trifluoromethyl)pyridine-3-carboxamide Chemical compound FC(F)(F)C1=CC=NC=C1C(=O)NC1CC2=CC=CC=C2CCC1 ISBRVCSGDWWGFN-UHFFFAOYSA-N 0.000 description 1
• IMAZKYUHKMGWDJ-UHFFFAOYSA-N n-(6,7,8,9-tetrahydro-5h-benzo[7]annulen-6-yl)-5,6,7,8-tetrahydroquinoline-3-carboxamide Chemical compound C1CCC2=CC=CC=C2CC1NC(=O)C1=CN=C(CCCC2)C2=C1 IMAZKYUHKMGWDJ-UHFFFAOYSA-N 0.000 description 1
• APWXJVPGKYKUIR-UHFFFAOYSA-N n-(6,7,8,9-tetrahydro-5h-benzo[7]annulen-6-yl)-5-(trifluoromethyl)thieno[3,2-b]pyridine-6-carboxamide Chemical compound C1CCC2=CC=CC=C2CC1NC(=O)C1=CC(SC=C2)=C2N=C1C(F)(F)F APWXJVPGKYKUIR-UHFFFAOYSA-N 0.000 description 1
• YNXVCALDOFGRRW-UHFFFAOYSA-N n-(6,7,8,9-tetrahydro-5h-benzo[7]annulen-6-yl)-6-(trifluoromethyl)pyridine-3-carboxamide Chemical compound C1=NC(C(F)(F)F)=CC=C1C(=O)NC1CC2=CC=CC=C2CCC1 YNXVCALDOFGRRW-UHFFFAOYSA-N 0.000 description 1
• RSYMBZUOGHWSKU-UHFFFAOYSA-N n-(6,7,8,9-tetrahydro-5h-benzo[7]annulen-6-yl)imidazo[1,2-a]pyridine-2-carboxamide Chemical compound C1CCC2=CC=CC=C2CC1NC(=O)C1=CN(C=CC=C2)C2=N1 RSYMBZUOGHWSKU-UHFFFAOYSA-N 0.000 description 1
• RXAICFUWEHWOAB-UHFFFAOYSA-N n-(6,7,8,9-tetrahydro-5h-benzo[7]annulen-6-yl)pyrimidine-4-carboxamide Chemical compound C1CCC2=CC=CC=C2CC1NC(=O)C1=CC=NC=N1 RXAICFUWEHWOAB-UHFFFAOYSA-N 0.000 description 1
• HXQXTHQEESRMNE-INIZCTEOSA-N n-[(6s)-6,7,8,9-tetrahydro-5h-benzo[7]annulen-6-yl]-3h-benzimidazole-5-carboxamide Chemical compound C1CCC2=CC=CC=C2C[C@H]1NC(=O)C1=CC=C(N=CN2)C2=C1 HXQXTHQEESRMNE-INIZCTEOSA-N 0.000 description 1
• BCDWJKJBNRSDDL-KRWDZBQOSA-N n-[(6s)-6,7,8,9-tetrahydro-5h-benzo[7]annulen-6-yl]-4-(2,2,2-trifluoroethoxy)benzamide Chemical compound C1=CC(OCC(F)(F)F)=CC=C1C(=O)N[C@@H]1CC2=CC=CC=C2CCC1 BCDWJKJBNRSDDL-KRWDZBQOSA-N 0.000 description 1
• YZMHQCWXYHARLS-UHFFFAOYSA-N naphthalene-1,2-disulfonic acid Chemical compound C1=CC=CC2=C(S(O)(=O)=O)C(S(=O)(=O)O)=CC=C21 YZMHQCWXYHARLS-UHFFFAOYSA-N 0.000 description 1
• 230000008692 neointimal formation Effects 0.000 description 1
• 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 235000001968 nicotinic acid Nutrition 0.000 description 1
• 229960003512 nicotinic acid Drugs 0.000 description 1
• 239000011664 nicotinic acid Substances 0.000 description 1
• 229910017604 nitric acid Inorganic materials 0.000 description 1
• 229920001220 nitrocellulos Polymers 0.000 description 1
• 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 description 1
• QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
• OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
• 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 230000008816 organ damage Effects 0.000 description 1
• 235000005985 organic acids Nutrition 0.000 description 1
• 239000012044 organic layer Substances 0.000 description 1
• 238000006053 organic reaction Methods 0.000 description 1
• 230000008520 organization Effects 0.000 description 1
• 230000003204 osmotic effect Effects 0.000 description 1
• 230000002018 overexpression Effects 0.000 description 1
• 235000006408 oxalic acid Nutrition 0.000 description 1
• 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 1
• FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
• 230000007170 pathology Effects 0.000 description 1
• 230000004796 pathophysiological change Effects 0.000 description 1
• 230000001991 pathophysiological effect Effects 0.000 description 1
• RGSFGYAAUTVSQA-UHFFFAOYSA-N pentamethylene Natural products C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 1
• 125000004817 pentamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
• 229960001412 pentobarbital Drugs 0.000 description 1
• 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
• 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
• 239000008194 pharmaceutical composition Substances 0.000 description 1
• 239000000546 pharmaceutical excipient Substances 0.000 description 1
• 239000002590 phosphodiesterase V inhibitor Substances 0.000 description 1
• 230000026731 phosphorylation Effects 0.000 description 1
• 238000006366 phosphorylation reaction Methods 0.000 description 1
• 125000003386 piperidinyl group Chemical group 0.000 description 1
• IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
• 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
• 229920000573 polyethylene Polymers 0.000 description 1
• 159000000001 potassium salts Chemical class 0.000 description 1
• 239000002244 precipitate Substances 0.000 description 1
• 125000001844 prenyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 239000003755 preservative agent Substances 0.000 description 1
• 235000019260 propionic acid Nutrition 0.000 description 1
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 230000001681 protective effect Effects 0.000 description 1
• 238000002331 protein detection Methods 0.000 description 1
• 102000004169 proteins and genes Human genes 0.000 description 1
• RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
• 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
• 238000011002 quantification Methods 0.000 description 1
• IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
• 230000007115 recruitment Effects 0.000 description 1
• 238000001953 recrystallisation Methods 0.000 description 1
• 238000011160 research Methods 0.000 description 1
• 208000037803 restenosis Diseases 0.000 description 1
• 230000002441 reversible effect Effects 0.000 description 1
• 229960004889 salicylic acid Drugs 0.000 description 1
• 239000000523 sample Substances 0.000 description 1
• 238000005070 sampling Methods 0.000 description 1
• 229960004617 sapropterin Drugs 0.000 description 1
• FNKQXYHWGSIFBK-RPDRRWSUSA-N sapropterin Chemical compound N1=C(N)NC(=O)C2=C1NC[C@H]([C@@H](O)[C@@H](O)C)N2 FNKQXYHWGSIFBK-RPDRRWSUSA-N 0.000 description 1
• 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
• 238000007086 side reaction Methods 0.000 description 1
• 229960002855 simvastatin Drugs 0.000 description 1
• RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
• 150000003384 small molecules Chemical class 0.000 description 1
• 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
• 239000011734 sodium Substances 0.000 description 1
• 239000011780 sodium chloride Substances 0.000 description 1
• 159000000000 sodium salts Chemical class 0.000 description 1
• 239000012453 solvate Substances 0.000 description 1
• 239000003381 stabilizer Substances 0.000 description 1
• 238000010186 staining Methods 0.000 description 1
• 238000010561 standard procedure Methods 0.000 description 1
• 239000008107 starch Substances 0.000 description 1
• 235000019698 starch Nutrition 0.000 description 1
• 239000008117 stearic acid Substances 0.000 description 1
• 230000000707 stereoselective effect Effects 0.000 description 1
• 125000005017 substituted alkenyl group Chemical group 0.000 description 1
• 238000006467 substitution reaction Methods 0.000 description 1
• 239000005720 sucrose Substances 0.000 description 1
• 238000006557 surface reaction Methods 0.000 description 1
• 239000003765 sweetening agent Substances 0.000 description 1
• 208000011580 syndromic disease Diseases 0.000 description 1
• 238000001308 synthesis method Methods 0.000 description 1
• 239000000454 talc Substances 0.000 description 1
• 229910052623 talc Inorganic materials 0.000 description 1
• 235000012222 talc Nutrition 0.000 description 1
• 239000011975 tartaric acid Substances 0.000 description 1
• 235000002906 tartaric acid Nutrition 0.000 description 1
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
• 238000002560 therapeutic procedure Methods 0.000 description 1
• 239000002562 thickening agent Substances 0.000 description 1
• 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
• 229930192474 thiophene Natural products 0.000 description 1
• 210000001519 tissue Anatomy 0.000 description 1
• 238000011200 topical administration Methods 0.000 description 1
• 238000012549 training Methods 0.000 description 1
• 230000026683 transduction Effects 0.000 description 1
• 238000010361 transduction Methods 0.000 description 1
• 238000012546 transfer Methods 0.000 description 1
• 210000003606 umbilical vein Anatomy 0.000 description 1
• 230000003827 upregulation Effects 0.000 description 1
• 230000000304 vasodilatating effect Effects 0.000 description 1
• 229940124549 vasodilator Drugs 0.000 description 1
• 239000003071 vasodilator agent Substances 0.000 description 1
• 230000001196 vasorelaxation Effects 0.000 description 1
• 235000015112 vegetable and seed oil Nutrition 0.000 description 1
• 239000008158 vegetable oil Substances 0.000 description 1
• 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
• 229940088594 vitamin Drugs 0.000 description 1
• 239000011782 vitamin Substances 0.000 description 1
• 229930003231 vitamin Natural products 0.000 description 1
• 235000013343 vitamin Nutrition 0.000 description 1
• 235000019158 vitamin B6 Nutrition 0.000 description 1
• 239000011726 vitamin B6 Substances 0.000 description 1
• 235000019154 vitamin C Nutrition 0.000 description 1
• 239000011718 vitamin C Substances 0.000 description 1
• 229940011671 vitamin b6 Drugs 0.000 description 1
• 239000001993 wax Substances 0.000 description 1
• 239000000080 wetting agent Substances 0.000 description 1
• BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
• 229960001600 xylazine Drugs 0.000 description 1